论文部分内容阅读
目的:探讨自噬活性相关蛋白Cathepsin-D、LC3表达与宫颈鳞状细胞癌耐药之间的关系。方法:选取宫颈鳞状细胞癌BOMP方案新辅助化疗敏感病例36例和耐药病例54例,应用免疫组织化学方法检测Cathepsin-D、LC3的表达,并对其临床病理参数进行对比分析。结果:Cathepsin-D在敏感组宫颈鳞状细胞癌中的阳性表达率为36%,在耐药组中阳性表达率为77%,差异有统计学意义(P<0.001);其表达水平与分化程度、浸润深度明显相关(r=-0.874,P<0.05和r=0.827,P<0.001),与临床分期、肿瘤体积、淋巴结转移无明显相关(P>0.05);LC3在敏感组宫颈癌中的表达率为87.1%,耐药组阳性表达率为78.5%,差别无统计学意义(P>0.05),其表达水平与肿瘤体积、临床分期明显相关(r=0.915,P<0.05和r=0.789,P<0.001),与分化程度、淋巴结转移、浸润深度之间无明显相关(P>0.05);两者在敏感组表达无相关性,在耐药组的表达存在明显相关(P<0.05)。结论:自噬活性改变参与宫颈鳞状细胞癌的发生发展和BOMP方案新辅助化疗的耐药机制,Cathepsin-D在其中发挥主要作用。
Objective: To investigate the relationship between the expression of Cathepsin-D, LC3 and the resistance of cervical squamous cell carcinoma. Methods: Thirty-six cases of neoadjuvant chemotherapy-sensitive cases of squamous cell carcinoma of cervix squamous cell carcinoma and 54 cases of resistant cases were selected. Expressions of Cathepsin-D and LC3 were detected by immunohistochemical method, and their clinicopathological parameters were compared. Results: The positive expression rate of Cathepsin-D in cervical squamous cell carcinoma was 36% in sensitive group and 77% in resistant group, the difference was statistically significant (P <0.001) (R = -0.874, P <0.05 and r = 0.827, P <0.001), but there was no significant correlation with clinical stage, tumor volume and lymph node metastasis (P> 0.05) (R = 0.915, P <0.05, r = 0.915, P <0.05). The positive expression rate was 87.1% in the drug resistance group and 78.5% in the drug resistance group, the difference was not statistically significant 0.789, P <0.001), and there was no significant correlation with the degree of differentiation, lymph node metastasis and depth of invasion (P> 0.05). There was no correlation between them in the sensitive group and in the resistant group ). CONCLUSIONS: Cathepsin-D plays a major role in the alteration of autophagy involved in the development of squamous cell carcinoma of the cervix and the drug resistance mechanism of neoadjuvant chemotherapy with BOMP regimen.